文献速递淋巴瘤浆细胞疾病

老年DLBCL患者一线R-CHOP后18个月内骨折常见

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

该多中心回顾性研究纳入10个英国中心2009-2019年连续收治的729例≥70岁、接受1-8周期足量或减量R-CHOP的DLBCL患者,随访自开始R-CHOP起至少6个月并在18个月截尾。

要点

  • 729例≥70岁DLBCL患者中,18个月内累积骨折发生率为11.4%(95%CI 9.3-14.0)。
  • 易感史、基线骨受累及前驱期激素是骨折的独立危险因素。

核心结论

  • 老年DLBCL患者接受R-CHOP后18个月内存在有临床意义的骨折风险及显著相关疾病负担。
  • 应重视接受R-CHOP老年患者的骨骼健康,并需随机研究明确降低骨折风险的最有效策略。

研究设计与样本

  • 英国10个中心2009-2019年连续收治的≥70岁DLBCL患者,接受1-8周期足量或减量R-CHOP,回顾性收集数据。
  • 共识别877例,排除121例6个月前进展或死亡、23例随访不足6个月,最终分析729例。
  • 自开始R-CHOP随访至少6个月,18个月截尾;若随访不足18个月则在末次随访截尾,或至进展/死亡截尾。
  • 729例中位年龄77岁,68%的ECOG体能状态评分为0-1。

主要发现

  • 累积骨折发生率:6个月6.2%(95%CI 4.7-8.2),12个月9.7%(95%CI 7.8-12.1),18个月11.4%(95%CI 9.3-14.0)。
  • 多因素分析显示易感史(骨质疏松、骨量减少、既往骨折、类风湿关节炎)、基线DLBCL骨受累及接受前驱期激素为骨折的独立危险因素。

临床怎么用

  • 对接受R-CHOP的老年DLBCL患者应仔细关注骨骼健康。
  • 对具有易感史、基线骨受累或接受前驱期激素者应加强骨折风险评估与监测。

局限性

  • 为回顾性多中心研究,可能存在数据收集与选择偏倚。
  • 排除6个月前进展或死亡及随访不足6个月者,可能影响风险估计。
  • 原文指出需要随机研究以明确降低骨折风险的最有效策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture are both more common in older patients. Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evidence is lacking to define fracture incidence in this group. Data on consecutive patients with DLBCL aged ≥70 years treated with 1 to 8 cycles of full or attenuated R-CHOP were retrospectively collected across 10 UK centers (2009-2019). Patients were followed up from starting R-CHOP for a minimum of 6 months and censored at 18 months; at last follow-up if <18 months; or at progression or death. Of 877 patients identified, 148 were excluded: 121 had progression or died before 6 months; 23 had follow-up <6 months. Across 729 remaining patients, the median age was 77 years, and 68% had an Eastern Cooperative Oncology Group performance status of 0 to 1. Eighty-one fractures occurred within 18 months of follow-up; 42 were symptomatic, including 30 requiring hospital attendance or admission. The cumulative fracture incidence was 6.2% (95% confidence interval [CI], 4.7-8.2) at 6 months; 9.7% (95% CI, 7.8-12.1) at 12 months; and 11.4% (95% CI, 9.3-14.0) at 18 months. Multivariate analysis identified a predisposing history (osteoporosis, osteopenia, prior fracture, and rheumatoid arthritis [RhA]), DLBCL bone involvement at baseline, and receipt of prephase steroids as independent risk factors for fracture. There is a clinically relevant fracture risk and significant associated morbidity in older patients receiving R-CHOP. Careful attention to bone health is warranted in older patients receiving R-CHOP. Randomized studies are required to better define the most effective strategies to reduce fracture risk.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Booth S, Plaschkes H, Kirkwood AA, et al. Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32915975. doi:10.1182/bloodadvances.2020002553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。